A dedicated phantom design for positron emission mammography performance evaluation.

No standardized testing framework currently exists for evaluating the performance of dedicated breast imaging scanners. Existing protocols for whole-body systems often fail to account for the unique geometry and requirements of breast-specific devices. This gap complicates the comparison of different scanners used in clinical settings. Prior research has focused on general positron emission tomography without addressing the specific needs of mammography applications. That uncertainty drove the development of specialized tools to quantify system capabilities accurately. Researchers have long recognized that breast lesions require high-resolution imaging to ensure diagnostic precision. No prior work had resolved how to adapt international standards to these smaller, specialized fields of view. This study addresses these limitations by proposing a dedicated phantom design tailored for breast-specific imaging performance assessment.

The aim of this work is to establish a standardized methodology for evaluating the performance of dedicated breast imaging systems. No prior work had resolved the lack of uniform protocols for these specialized scanners. This gap motivated the development of custom phantoms that mimic the physical characteristics of breast lesions. The researchers sought to adapt existing international standards to fit the unique geometry of breast-specific positron emission tomography. They intended to provide a reliable framework for quantifying spatial resolution and contrast detectability in a clinical context. The study also explores the impact of different radionuclides on system performance to ensure broad applicability. By creating these tools, the authors hope to facilitate consistent quality assurance across different imaging platforms. This research addresses the urgent need for objective metrics in the assessment of dedicated breast-specific devices.

The review approach involves creating specialized phantoms that replicate the physical dimensions of clinical breast lesions. Investigators integrated these tools with existing international guidelines originally intended for whole-body positron emission tomography systems. The team performed rigorous testing on the Flex Solo II scanner to validate the new methodology. They assessed spatial resolution by analyzing point-like sources and sphere detectability across various sizes. Uniformity was quantified by calculating standard deviations within the reconstructed images to ensure consistent signal distribution. The researchers examined positron range effects by comparing imaging outcomes between two distinct radionuclides with different energy profiles. They calculated recovery coefficients using a series of hot rods to determine the system's ability to resolve small structures. Finally, the study measured spill-over ratios to evaluate the impact of background activity on image contrast and clarity.

Key findings from the literature demonstrate that the system achieves an in-plane spatial resolution of 3.0 mm for 18F and 4.4 mm for 68Ga. Lesion detectability tests confirmed that the scanner successfully resolves all spheres ranging from 4 to 10 mm in diameter. Percent contrast values for 18F hot spheres reached up to 38%, while 68Ga values peaked at 25%. Uniformity measurements showed percentage standard deviations between 4.9% and 5.7% across all tested configurations. Background variability remained consistent, ranging from 6.7% to 10.9% for both isotopes. Recovery coefficients for 18F hot rods varied between 0.2 and 1.05, reflecting the system's sensitivity to structural size. The researchers observed an average spill-over ratio of 0.22, indicating the level of background interference present in the images. These results establish a quantitative baseline for evaluating the performance of dedicated breast imaging systems.

The authors propose that their custom phantom design provides a robust foundation for future standardized image quality protocols. These findings suggest that the methodology effectively quantifies critical performance metrics like spatial resolution and lesion detectability. The researchers conclude that their approach allows for consistent evaluation across different radionuclides with varying energy spectra. Synthesis and implications indicate that this framework could be extended to other dedicated breast-specific PET scanners. The data show that the system maintains reliable performance even when using isotopes with different decay characteristics. This work highlights the necessity of using lesion-sized components to accurately reflect clinical imaging conditions. The authors emphasize that their methodology bridges the gap between general PET standards and specialized breast imaging requirements. These results provide a clear path forward for establishing uniform quality assurance practices in clinical breast imaging.